CND Life Sciences Advances Parkinson's Study with New Grant

CND Life Sciences Receives Grant to Support Parkinson's Research

Grant funding will support the new Syn-Q Clinical Study to further investigate the quantification of P-SYN in skin biopsies using CND's Syn-One Test.

CND Life Sciences, a medical technology company pioneering the development of dermal neurodiagnostic tests and related biomarker services, has been awarded a significant grant. This funding aims to assist in a clinical initiative called the Syn-Q Study, which seeks to quantify phosphorylated alpha-synuclein in patients with Parkinson's disease over a specified period.

Understanding the Importance of P-SYN

P-SYN stands for phosphorylated alpha-synuclein, a crucial biomarker associated with Parkinson's disease and other synucleinopathies. The Syn-One Test is a cutting-edge skin biopsy assay designed to detect this biomarker within cutaneous nerves, providing essential insights into the progression of Parkinson's disease.

According to Todd Levine, MD, Chief Medical Officer at CND Life Sciences, the grant from The Michael J. Fox Foundation for Parkinson's Research is a crucial step in the endeavor to monitor and quantify the progression of alpha-synuclein accumulation. This initiative is expected to enhance the understanding of Parkinson's disease and ultimately contribute to improving patient outcomes.

Details on the Syn-Q Study

The Syn-Q study aims to enroll a total of 100 participants, including 75 patients diagnosed with Parkinson's disease and an additional 25 patients suffering from REM Sleep Behavior Disorder (RBD). By including a diverse participant pool across various genders, racial backgrounds, and levels of disease severity, the study will collect longitudinal clinical assessments and skin biopsies to accurately track the evolution of phosphorylated alpha-synuclein within patients.

In recent months, the Syn-One Test has shown promising results in clinical evaluations, demonstrating an impressive detection rate for phosphorylated alpha-synuclein in individuals with clinically confirmed synucleinopathies. Reports indicate that the Syn-One Test was able to detect this biomarker in 95% of patients diagnosed with synucleinopathy.

Collaboration and Future Potential

CND Life Sciences collaborates with multiple pharmaceutical partners to utilize the Syn-One Test in clinical development. This collaboration aims to identify appropriate patient populations and measure changes in synuclein deposition over time, thereby improving treatment responses and monitoring disease progression in patients.

Christopher Gibbons, MD, Chief Scientific Officer of CND Life Sciences, expressed excitement for the funding support which will allow further advancements in their Syn-One technology. He believes the study will offer valuable insights into the natural progression of phosphorylated alpha-synuclein accumulation in Parkinson's patients and will enhance the capability to determine therapeutic impacts.

About CND Life Sciences

CND Life Sciences is committed to supporting patients who may face diagnoses of neurodegenerative diseases and neurological conditions. CND operates a CLIA-certified and CAP-accredited laboratory equipped to conduct thorough assessments, including the Syn-One Test, which is designed to assist clinicians in diagnosing Parkinson's disease and related disorders.

The Syn-One Test employs proprietary immunofluorescence techniques to effectively visualize and quantify phosphorylated alpha-synuclein in tissue samples obtained from skin biopsies. This testing process involves minimal patient discomfort and aims to provide unprecedented sensitivity in diagnostic evaluations, reaching over 95% sensitivity in clinically diagnosed synucleinopathies.

Approximately 2,000 professionals, including neurologists, have embraced the use of the Syn-One Test to aid in their diagnostic procedures across the nation. Additionally, CND Life Sciences actively collaborates with biopharmaceutical companies to conduct clinical trials focused on neurodegenerative therapies, fostering advancement in early disease detection and prognostic insight.

Frequently Asked Questions

What is the purpose of the Syn-Q Study?

The Syn-Q Study aims to quantify phosphorylated alpha-synuclein in skin biopsies from patients with Parkinson's disease and REM Sleep Behavior Disorder.

How does the Syn-One Test work?

The Syn-One Test employs skin biopsies to detect and visualize phosphorylated alpha-synuclein in cutaneous nerves, serving as a biomarker for diagnosing Parkinson's disease.

Who is funding the Syn-Q Study?

The funding for the Syn-Q Study comes from The Michael J. Fox Foundation for Parkinson's Research.

How many participants will be involved in the study?

The study plans to enroll 100 participants, including 75 with diagnosed Parkinson's disease and 25 with REM Sleep Behavior Disorder.

What are the expected outcomes of this research?

The research aims to enhance understanding of phosphorylated alpha-synuclein's role in Parkinson's disease and improve patient treatment strategies through better diagnosis and monitoring.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.